Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley. (3rd August 2021)

• Record Type: Journal Article
• Authors: Melotti, Roberto; Scaggiante, Federica; Falciani, Michela; Weichenberger, Christian X.; Foco, Luisa; Lombardo, Stefano; De Grandi, Alessandro; von Laer, Dorothee; Mahlknecht, Angelika; Pramstaller, Peter P.; Pagani, Elisabetta; Meier, Horand; Gaertner, Timon; Troi, Christina; Mascalzoni, Deborah; Pattaro, Cristian; Mian, Michael
• Is Part Of: Epidemiology and infection. Volume 149(2021)
• Publication Date: 2021-08-03
• Subjects: Coronavirus -- COVID-19 -- neutralising antibodies -- prevalence -- SARS-CoV-2; Communicable diseases -- Periodicals; Epidemiology -- Periodicals; 614.4
• DOI: 10.1017/S0950268821001886
• Languages: English
• ISSNs: 0950-2688

Abstract

Abstract: Estimating the spread of SARS-CoV-2 infection in communities is critical. We surveyed 2244 stratified random sample community members of the Gardena valley, a winter touristic area, amidst the first expansion phase of the COVID-19 pandemic in Europe. We measured agreement between Diasorin and Abbott serum bioassay outputs and the Abbott optimal discriminant threshold of serum neutralisation titres with recursive receiver operating characteristic curve. We analytically adjusted serum antibody tests for unbiased seroprevalence estimate and analysed the determinants of infection with non-response weighted multiple logistic regression. SARS-CoV-2 seroprevalence was 26.9% (95% CI 25.2–28.6) by June 2020. The bioassays had a modest agreement with each other. At a lower threshold than the manufacturer's recommended level, the Abbott assay reflected greater discrimination of serum neutralisation capacity. Seropositivity was associated with place and economic activity, not with sex or age. Symptoms like fever and weakness were age-dependent. SARS-CoV-2 mitigation strategies should account for context in high prevalence areas.